Why Bicycle Therapeutics Stock Is Soaring Today

Vandana Singh
1 min read
0
In this article:

  • Bicycle Therapeutics plc (NASDAQ: BCYC) has announced interim Phase 1 results from the Phase 1/2 trial of BT8009, a second-generation BTC targeting Nectin-4, in patients with advanced solid tumors.

  • The data will be presented at the 2022 American Association for Cancer Research Annual Meeting.

  • Patients were treated until disease progression or intolerable toxicity, with tumor assessments for response per RECIST taken every two months.

  • One dose-limiting toxicity (Grade 3 abnormal physical weakness) was reported at the 7.5 mg/m2 weekly dose level. Six patients (18%) experienced an SAE, with only one related SAE (vomiting).

  • Related: Bicycle Therapeutics Stock Falls After Interim Data Of Toxin Conjugates In Ovarian Cancer Trial.

  • In the urothelial carcinoma (UC) 5 mg/m2 cohort, a 50% overall response rate and a 75% disease control rate were observed.

  • 4/8 patients with a complete response (CR) or partial response (PR), including 1/8 patients with a CR and 3/8 patients with a PR, and 2/8 patients (25%) with stable disease (SD).

  • BT8009 exhibits a promising preliminary tolerability profile and preliminary antitumor activity.

  • The molecule will continue to be explored in the current dose-escalation/dose-expansion study of BT8009 monotherapy and combination with Bristol Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab).

  • Price Action: BCYC shares are up 25.40% at $47.34 during the market session on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories